Predict your next investment

Angel Investor (Group)
FINANCE | Investment Firms & Funds
bluewaterangels.com

See what CB Insights has to offer

Investments

39

Portfolio Exits

5

Funds

1

About BlueWater Angels

BlueWater Angels (BWA) is a network of more than 50 high-net-worth individuals and select organizations interested in investing capital in promising companies with the expectation of receiving a substantial return on their investment.

BlueWater Angels Headquarters Location

1320 N Michigan Ave Suite 6

Saginaw, Michigan, 48602,

United States

989-839-2333

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

BlueWater Angels Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BlueWater Angels Rank

Latest BlueWater Angels News

Biotech firm RetroSense Therapeutics picks up $6 mln

Jan 9, 2015

January 9, 2015     0 Comments Ann Arbor, Michigan-based biotech firm RetroSense Therapeutics has received $6 million in a Series A financing. The investors included Nerveda, Blue Water Angels, SDL Ventures, Tech Coast Angels and Michigan Economic Development Corp. PRESS RELEASE ANN ARBOR, Mich.–(BUSINESS WIRE)–RetroSense Therapeutics (www.retro-sense.com), a privately-held biopharmaceutical company, today announced that it has secured $6 million in a Series A financing to further investigate the use of gene therapy and optogenetics to restore vision loss. The investment syndicate includes Nerveda, Blue Water Angels, SDL Ventures, Tech Coast Angels, and Michigan Economic Development Corporation. The proceeds should enable completion of preclinical studies needed to support an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration for its lead compound, RST-001 for the treatment of Retinitis Pigmentosa, a cause of vision loss and blindness. “We believe this financing round should provide us with sufficient capital resources to support our IND filing in early 2015 for our lead product, RST-001,” said Sean Ainsworth, CEO of RetroSense Therapeutics. “We are focused on developing novel treatment options for patients with severe vision loss due to retinitis pigmentosa and completion of our preclinical studies will be the next step towards filing an IND and initiating clinical trials.” Optogenetics refers broadly to means of conferring light sensitivity to cells that were not previously, or natively light sensitive. By applying optogenetics to retinas in which rod and cone photoreceptors have degenerated, RetroSense is conferring new light sensitivity to the retina, with the expectation of improved or restored vision. RST-001 is expected to have application to all forms of retinitis pigmentosa, independent of causative gene or mutation. Recently designated with Orphan Drug Status, RST-001 is being developed as a first-in-class gene therapy application of optogenetics designed to restore vision to those affected by retinal degenerative conditions. About Retinitis Pigmentosa Retinitis pigmentosa is a genetic condition which leads to the progressive degeneration of rod and cone photoreceptors (cells found in the retina of the eye that sense light). Loss of these cells results in severe vision loss and blindness. About RetroSense Therapeutics RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The Company’s approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. RetroSense has worldwide exclusive rights to the relevant intellectual property from both institutions. RetroSense is led by a team of seasoned veterans with deep experience in taking products from the discovery stage through to the clinic. For more information about RetroSense, visit http://www.retro-sense.com/. Leave a Reply

BlueWater Angels Investments

39 Investments

BlueWater Angels has made 39 investments. Their latest investment was in Ocuphire Pharma as part of their Series A on July 7, 2019.

CBI Logo

BlueWater Angels Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/22/2019

Series A

Ocuphire Pharma

$5M

Yes

10

10/3/2018

Seed VC

GreenMark Biomedical

$0.61M

Yes

1

12/16/2015

Series A - II

foodjunky

$0.42M

Yes

3

11/12/2015

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/15/2015

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/22/2019

10/3/2018

12/16/2015

11/12/2015

4/15/2015

Round

Series A

Seed VC

Series A - II

Series B

Series B

Company

Ocuphire Pharma

GreenMark Biomedical

foodjunky

Subscribe to see more

Subscribe to see more

Amount

$5M

$0.61M

$0.42M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

1

3

10

10

BlueWater Angels Portfolio Exits

5 Portfolio Exits

BlueWater Angels has 5 portfolio exits. Their latest portfolio exit was VNN on March 02, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/2/2022

Merger

$99M

1

6/18/2020

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

6/6/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

9/6/2016

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/16/2015

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/2/2022

6/18/2020

6/6/2018

9/6/2016

7/16/2015

Exit

Merger

Reverse Merger

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

BlueWater Angels Fund History

1 Fund History

BlueWater Angels has 1 fund, including GREAT LAKES BAY VENTURE FUND I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

GREAT LAKES BAY VENTURE FUND I

Early-Stage Venture Capital

Open

1

Closing Date

Fund

GREAT LAKES BAY VENTURE FUND I

Fund Type

Early-Stage Venture Capital

Status

Open

Amount

Sources

1

BlueWater Angels Team

1 Team Member

BlueWater Angels has 1 team member, including current President, Kenneth Kousky.

Name

Work History

Title

Status

Kenneth Kousky

President

Current

Name

Kenneth Kousky

Work History

Title

President

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.